With up to 400 million influenced individuals around the world, constant hepatitis B infection (HBV) contamination is as yet a noteworthy medicinal services issue. Amid the most recent decade, a few novel helpful methodologies have been produced and assessed. In many locales of the world, interferon-α, and nucleos(t)ide analogs (NUCs) are as of now affirmed. In spite of real enhancements, none of the current treatments is ideal since viral freedom is seldom accomplished. As of late, a superior comprehension of the HBV life cycle and the advancement of novel model frameworks of HBV disease have prompted the improvement of novel antiviral procedures and medication targets. This survey will concentrate on present and potential future medication focuses in the HBV life cycle and systems to balance the virus– have connection.
Key Words: hepatitis B virus, , interferon-α, rcDNA, Antiviral agents.